Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK129 with chemotherapy with or without cadonilimab in first-line advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma
CTR20242613Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Jul 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AK129 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Akeso, Inc.. Started Jul 2024; status: completed.
02
Drugs
AK129
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20242613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242613.